Critical Comparison: Bullfrog AI (NASDAQ:BFRG) and InflaRx (NASDAQ:IFRX)

Bullfrog AI (NASDAQ:BFRG) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a summary of recent recommendations for Bullfrog AI and InflaRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	0	0	0	0	0.00
InflaRx	0	0	1	0	3.00

InflaRx has a consensus target price of $8.00, indicating a potential upside of 249.34%. Given InflaRx’s stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than Bullfrog AI.

Institutional and Insider Ownership

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 33.9% of Bullfrog AI shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Bullfrog AI has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Profitability

This table compares Bullfrog AI and InflaRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-141.39%	-124.63%
InflaRx	-33,362.70%	-65.98%	-56.86%

Valuation & Earnings

This table compares Bullfrog AI and InflaRx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$60,000.00	361.59	-$5.36 million	($0.85)	-2.93
InflaRx	$168,498.00	800.26	-$46.18 million	($1.08)	-2.12

Bullfrog AI has higher earnings, but lower revenue than InflaRx. Bullfrog AI is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Summary

InflaRx beats Bullfrog AI on 10 of the 14 factors compared between the two stocks.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.